SCHEMBL21137987

SCHEMBL21137987

CCc1cc(F)c(Cl)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 2/20 0.39
▸ KDM1B Q8NB78 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ GPR84 Q9NQS5 1/20 0.37
▸ GRIN2D O15399 1/20 0.36
▸ GRIN3B O60391 1/20 0.36
▸ GRIN1 Q05586 1/20 0.36
▸ GRIN2A Q12879 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ GRIN2C Q14957 1/20 0.36
▸ GRIN3A Q8TCU5 1/20 0.36
▸ HTR2A P28223 3/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ BRD9 Q9H8M2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17071835 0.91 TSHR (0.38) TSHRGPR84GRIN2DGRIN3BGRIN1
SCHEMBL15132116 0.88 TSHR (0.39) KDM1AKDM1BTSHRGPR84GRIN2D
SCHEMBL22964357 0.86 GRIN2D (0.45) KDM1AKDM1BTSHRGPR84GRIN2D
SCHEMBL5023529 0.86 GRIN2D (0.45) KDM1AKDM1BTSHRGPR84GRIN2D
SCHEMBL19489957 0.84 DPP4 (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11936747 0.83 GRIN2D (0.47) KDM1AKDM1BTSHRGRIN2DGRIN3B
SCHEMBL17450427 0.82 CD44 (0.38) TSHRGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL6817121 0.79 DPP4 (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL12447340 0.79 GRIN2D (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL31459934 0.79 GRIN2D (0.36) TSHRGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208923-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION JNANA THERAPEUTICS INC. 2024-06-27 — — US disclosed
US-20200352931-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Phenex Discovery Verwaltungs-GmbH (DE) 2020-11-12 — — US disclosed
WO-2019115586-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Phenex Discovery Verwaltungs-GmbH (DE) 2019-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200352931-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT KDM1A 321/4885KDM1B 371/4885TSHR 3891/4885
US-20240208923-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION SLC18A2, SLC6A19, SLC1A1 KDM1A 4524/4885KDM1B 4032/4885TSHR 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback